Cadrenal Therapeutics (CVKD) Lytham Partners 2025 Investor Healthcare Summit summary

Leadership background and mission

• CEO's experience in pharmaceuticals and personal connection to anticoagulation therapies shaped the focus on tecarfarin.

• Commitment to advancing tecarfarin for patients unable to use newer anticoagulants, especially those dependent on warfarin.

• Focus on rare cardiovascular conditions, particularly advanced heart failure patients with LVADs.

• Perseverance through challenging biotech market conditions by securing investors and partners.

Tecarfarin's role and clinical rationale

• Tecarfarin targets patients with rare cardiovascular conditions where DOACs are ineffective, such as ESKD with AFib and LVAD patients.

• Demonstrated improved anticoagulation and stable metabolism in patients with chronic kidney disease compared to warfarin.

• Potential for fewer side effects and better outcomes in LVAD patients, supported by ongoing discussions with Abbott and the FDA.

Industry landscape and clinical data

• Cardiovascular disease remains the leading cause of death and is under-invested compared to other therapeutic areas.

• Recent studies, including the ARES study led by Dr. Mandeep Mehra, showed that removing aspirin from LVAD regimens reduced bleeding risks.

• Maintaining patients in the therapeutic range is critical for reducing complications in LVAD patients.

• Monitoring remains essential for effective anticoagulation, especially with tecarfarin.